Gilead Sciences Inc. (GILD)

76.84
0.70 0.90
NASDAQ : Health Technology
Prev Close 77.54
Open 76.75
Day Low/High 76.20 / 77.53
52 Wk Low/High 60.89 / 85.97
Volume 7.90M
Avg Volume 21.89M
Exchange NASDAQ
Shares Outstanding 1.25B
Market Cap 93.30B
EPS 4.20
P/E Ratio 19.08
Div & Yield 2.72 (3.51%)
Cramer: The Stock Market Is Now Divided Into 3 Buckets - And One Is Unfortunate

Cramer: The Stock Market Is Now Divided Into 3 Buckets - And One Is Unfortunate

The problem for index fund owners is they own all three buckets and there are a lot more companies in the third bucket than in the first two.

Takeaways for a Not-so-Great Day

It was another day in which there was some bad news out of Gilead and the bad economic data continues. From my perch, Mr. Market is doing a good job of consolidating a spectacular gain from the mid-March bottom. * Oil +$3.20/barrel. (And energy stoc...

What the Bears Want

In Twitter feeds I can feel the Bears rooting for the markets to go down. (While anything can happen) I am not so sure it's going to happen today - even with the Gilead news. I will end the day longer than I started the day.

Jim Cramer: This Market Values Companies With a Heart

Jim Cramer: This Market Values Companies With a Heart

Brains per share. Hearts Per Share. I've been around long enough to be that positive. I like these companies and more importantly, I like their stocks.

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.

How I See Market Performance Evolving Over Time, Trading Advanced Micro

How I See Market Performance Evolving Over Time, Trading Advanced Micro

Will tech continue to trend toward leadership? Who among us can remember when it has not?

Gilead Cut to Market Perform at BMO

The Week Ahead: Jobless Claims, PMI Data and 35 Key Earnings Reports to Watch

The Week Ahead: Jobless Claims, PMI Data and 35 Key Earnings Reports to Watch

More than 450 quarterly reports are on tap, including 105 S&P 500 constituents.

Gilead, Costco and Amazon: 3 Top Pandemic Stocks for DRIP Investors

Gilead, Costco and Amazon: 3 Top Pandemic Stocks for DRIP Investors

Long-term investors must buy during bear markets -- and these companies offer dividend reinvestment or direct investment plans to help seize the opportunity.

Jim Cramer: I'm Very Concerned About a Breakdown in Oil Here

Jim Cramer: I'm Very Concerned About a Breakdown in Oil Here

I have to believe that a few more weeks of lower oil prices and we will see more bankruptcy filings.

We're at a Crossroads and Friday's Close Is Going to Be Huge

We're at a Crossroads and Friday's Close Is Going to Be Huge

Today is about hope on two fronts: the markets and society.

Maintaining Optimism in a Surreal Pandemic Environment

Maintaining Optimism in a Surreal Pandemic Environment

I never understood why my state of Florida, with vastly fewer deaths, is on the same sort of lockdown as New York.

Gilead Surges on Remdesivir Report: How to Play the Stock Now

Gilead Surges on Remdesivir Report: How to Play the Stock Now

We have a new price target for GILD.

Shorting Apple ($289.75 pre-market trading)

* For investment and placing stock on my Best Ideas List I'll get into the tactical moves I made last night (after the S&P futures rose by nearly +90 handles in response to the Gilead Sciences drug news), but I wanted to mention that I am shorting A...

Less Gold

From early last night - I sold down my position based on "The Smartest Trader" comments that the rise in gold was looking "tired", the reduced reward vs. risk (short term), and because of the positive equity impact on the Gilead drug announcement (a...

Bears Are Capitulating but This Still Is Just a Very Large Counter-Trend Bounce

Bears Are Capitulating but This Still Is Just a Very Large Counter-Trend Bounce

There is likely to be some period of consolidation as market players assess the many crosscurrents that are occurring.

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.

This Market Has Been Rangebound on Derivatives Exposure

This Market Has Been Rangebound on Derivatives Exposure

Friday is the April expiration for S&P 500 index options -- and that can explain more or less why the market has been so tightly pinned.

My New Multi-Group Portfolio Strategy for Trading the Pandemic

My New Multi-Group Portfolio Strategy for Trading the Pandemic

How has my book evolved since the Fed and Treasury rode into town? Here's how.

Jim Cramer: Don't Mistake the Rally for Cheering

Jim Cramer: Don't Mistake the Rally for Cheering

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.

Jim Cramer: Now We're Seeing a Work in Progress

Jim Cramer: Now We're Seeing a Work in Progress

As testing expands, drug trials proceed and tech greats are providing a tracking app, I think we're inching toward going back to work -- and further away from going so low again.

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.

Let's Cut Through All the Noisy Trading in Gilead Sciences

Let's Cut Through All the Noisy Trading in Gilead Sciences

Trading action has been jumpy, so where's the trend?

Market Review, Adapting to Change, Notes on 4 Stocks, Trading Gilead Sciences

Market Review, Adapting to Change, Notes on 4 Stocks, Trading Gilead Sciences

Over the past month, 3 sectors have revealed themselves as market leaders: Technology, Healthcare and Consumer Staples.

Some Optimism, Watching Oil, Trading Hain, Updating 4 Stocks: Market Recon

Some Optimism, Watching Oil, Trading Hain, Updating 4 Stocks: Market Recon

The presidential task force wasn't going to address the media Sunday. Then, they did. Actual news? Futures markets opened ahead of that, in the green, and went higher. That's interesting.

Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform

Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform

For March and the first quarter, the RMPIA takes less of a hit than major indexes.

Jim Cramer: Here Are the Quarter's Winners, Losers

Jim Cramer: Here Are the Quarter's Winners, Losers

The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.